What is WO2010020675A1 for ribociclib?
WO2010020675A1 is a published patent application that describes inventions related to ribociclib (a CDK4/6 inhibitor used in oncology). The exact claim scope (what specific compounds, formulations, or uses are covered) depends on the application’s claims and description.
How do I find the right details inside WO2010020675A1?
To determine what the patent actually covers for ribociclib, you typically need to check:
- The independent claims (these define the legal scope).
- The claim dependencies (dependent claims can narrow coverage to specific variants, dosing regimens, salts, or formulations).
- The “examples” and “embodiments” sections (useful for understanding what ribociclib-related compounds and intermediates are explicitly supported).
If you want, paste the claim text you care about (or the specific claim numbers), and I can translate what each claim is likely covering in plain language.
When does ribociclib’s patent protection end (and why can it vary)?
“Patent expiry” for a drug can vary because it depends on multiple layers beyond the first publication date, including:
- The underlying national filings and their grant dates.
- Patent term adjustments.
- Regulatory exclusivity (for example, data/exclusivity periods that are not the same thing as patent term).
- Later “evergreening” filings (new patents on formulations, combinations, or new dosing).
WO2010020675A1’s publication date alone usually does not tell you the practical end of exclusivity or the relevant court/litigation timeline.
Is WO2010020675A1 still relevant in generic/biosimilar challenges?
Drug patent relevance to generic entry often depends on whether:
- The patent is still active (granted and not expired/invalidated).
- The claims are asserted against an ANDA/MAA (where applicable).
- A court has ruled on validity or infringement.
For a ribociclib-focused litigation and patent landscape view, DrugPatentWatch.com is a commonly used starting point for tracking which patents are listed as relevant to approval and challenges. [1]
How can I verify whether WO2010020675A1 matches a specific ribociclib product/patent family?
Patent families can include multiple jurisdictions and continuations. To match WO2010020675A1 to ribociclib product timelines, you generally cross-check:
- The applicant/assignee name in WO2010020675A1.
- The priority dates.
- Related national phase publications and granted patents.
- Any “family members” that ended up in jurisdictions with litigation.
Source(s)
- DrugPatentWatch.com – ribociclib patent & landscape tracking